skip to Main Content
NHS Launching Patient Registry To Support Evidence Base For Cannabis Medicines

By Peter McCusker

THE NHS is to launch is first-ever cannabis patient registry in a move which signifies an ambition for the medicines to become more widely-available to UK patients.

Health Secretary Matt Hancock ordered an urgent review into the lack of cannabis prescriptions, last spring.

The creation of a patient database was one of the recommendations of the subsequent report; ‘Barriers to accessing cannabis-based products for medicinal use on NHS prescription’

The NHS has now confirmed to BusinessCann that this will now be launched early next year entitled the Patient Registry for Cannabis-Based Products.

This announcement has been welcomed, as a lack of data on the efficacy of medical cannabis has been one reason highlighted for a woeful lack of prescriptions through the NHS.

However, unless the database is also opened up the the private sector then it may well fail to achieve its desired goals, says one of the country’s leading cannabis doctors

Muhammed Vohra, Principal Business Analyst at Arden & GEM, and project lead on the patient registry for the NHS, said: “By enabling the standardised collection of data for all patients being prescribed cannabis-based products, to treat certain medical conditions, our aim is to improve patient care through robust monitoring and evaluation.

“For users, the registry supports clinical decisions to be taken, based on the latest guidance, so that we can keep patients safe while gaining better clinical evidence about the potential impact of these fairly recently rescheduled products.”

As things stand in the UK, there are three licensed cannabis medicines; Sativex, Epidyolex and Nabilone with around 100 patients said to be receiving monthly prescriptions.

However, most cannabis patients and their clinicians prefer the unlicensed medicines which allow for a greater diversity in prescription based on relevant THC and CBD ratios.

Just three patients on the NHS are currently allowed access to the these and, as a result, some fear the registry will therefore be unable to gather the required data.

There are believed to be up to 2,000 patients in the UK currently accessing ‘full spectrum’ medicines through the growing band of private UK clinics.

Is It A waste Of Time?

This was a point taken up by one of the country’s leading medical cannabis clinicians Prof Mike Barnes, Chair of the UK Medical Cannabis Clinicians Society.

He told BusinessCann: “I welcome the idea and and hope it will be used positively to support greater NHS prescriptions, as soon as possible.

“However the flaw in an NHS-only registry is that it will tell us nothing on the use of full spectrum products as there are not any NHS prescriptions, except for the three children. In other words it may well be a waste of time, unless the private sector contributes.”

This point was taken up by Mary Biles O’Mahony, Medical Cannabis Journalist and Educator, who said: “It’s great news to see the patient registry for Cannabis-based products for medicinal use (CBPM) launching in the new year.

“Hopefully the data recorded will inspire confidence in specialist doctors within the NHS who until now have been reticent about prescribing cannabis-based medicines citing a lack of evidence and a concern about side effects.

“However, because prescriptions within the NHS have largely been for licensed cannabis-based medicines such as Sativex or Epidyolex, the registry will hold very little information about unlicensed CBPMs which are, on the whole, only prescribed in private clinics; potentially further cementing the great divide between CBPM prescription within the NHS and the private sector.”

Mitigating Cultural Baggage

Gavin Sathianathan is founder of Alta Flora, the creators of Eva, a patient data app that records the effectiveness of cannabis medicines for patients through the Project Twenty21 initiative.

He said: “The registry provides the opportunity for patients to share their experiences with medical cannabis and help to develop the evidence base that will shape how medical cannabis is regulated, prescribed and administered in the future. Having a data-driven conversation about medical cannabis can go some way in mitigating its cultural and political baggage.”

The NHS Arden & GEM Commissioning Support Unit says the registry will be a web-based application, developed with input from specialist prescribers, clinicians, the National Institute for Health and Care Excellence (NICE) and the Medicines and Health products Regulatory Agency (MHRA).

In a statement to BusinessCann it went on to say: “It enables prescribers to record information about patients, episodes of care, review requirements and response to medication including patient reported experience and outcomes.

“Any side effects or reactions to cannabis-based products for medicinal use will automatically populate the MHRA ‘yellow card scheme’ which collects information on medicines and medical devices to identify safety concerns.

“The data is held in a secure cloud-based environment, with bespoke data-flows available to service reporting and dashboard needs related to evaluating clinical effectiveness, developing commissioning policy and monitoring outcomes.”

Private sector cannabis patient registers are already collating data in the UK. These include Project Twenty21 and the Sapphire Medical Cannabis Registry.

One further recommendation of the  ‘Barriers to accessing cannabis-based products for medicinal use on NHS prescription’ was the launch of a series of Randomised Control Trials into epilepsy. This has yet to progress with patient groups objecting to the trial design.

Peter McCusker

Peter McCusker

Peter McCusker is the Founder and Editor of BusinessCann and an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant. BusinessCann covers the ins and outs of the growing European Regulated Medical Marijuana marketplace. Peter can be reached at [email protected].

BusinessCann is an online news publication, which supports the growth of Europe’s Hemp, CBD and Medicinal Cannabis industries by providing factual and feature articles, comment and profiles on the people and businesses forging its growth and development.
This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Group forms to help give equal access to Connecticut’s new cannabis market

A new association has been formed to ensure Black and other under represented communities will have an opportunity to participate in Connecticut’s new legalized recreational marijuana industry, as state legislators had promised. The Alliance for Cannabis Equity, or ACE, created by two local workforce and economic development organizations, will host various programs to help aspiring…

Phoenix Rising: Will Terry Booth’s Audacious New Game Plan Succeed?

Australis Capital Inc. (CSE:AUSA) (OTC:AUSAF) CEO Terry Booth, who famously started Aurora Cannabis in 2006 before departing under duress in 2019, has a lot on his mind and his plate these days as he undertakes for the second time in his career the truly formidable task of steering a large cannabis venture into market relevance.…

Top 5 Communications Strategies According to Publicity Experts

Every cannabis and cannabis-related brand needs publicity to spread the word, boost awareness, and motivate people to buy its products and services. The challenge for businesses working in and with the cannabis industry is determining how to invest their time and marketing budgets to get publicity that actually drives the type of engagement that leads…

Delta-9 THC Products from Hemp Are a Risk Not Worth Taking

The hemp-derived cannabinoid market continues to grow and evolve despite lingering questions over federal legality and numerous state laws that try to keep pace. Much has been written about new “legal” hemp products that contain intoxicating delta-8 THC, delta-10 THC and THC-O Acetate. This article, however, seeks to highlight a brazen new use for familiar…

More Categories

Back To Top
×Close search
Search